Opioid Use Disorder Clinical Trials

Find Opioid Use Disorder Clinical Trials Near You

Targeting Reinforcement Mechanisms for Smoking Cessation Using Very Low Nicotine Content Cigarettes in Individuals With Opioid Use Disorder and Chronic Pain

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to evaluate the effects of switching to very low nicotine content (VLNC) cigarettes versus normal nicotine content (NNC) cigarettes on craving, withdrawal, and pain among individuals with chronic pain who smoke cigarettes daily and are attending office-based buprenorphine treatment (OBBT).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Healthy Volunteers: f
View:

• Aged 21+ years who smoke cigarettes daily

• Chronic non-cancer musculoskeletal pain secondary to structural changes (e.g., low back pain, osteoarthritis)

• Have received stable office-based buprenorphine treatment for opioid use disorder for at least 30 days

• Self-report smoking at least 10 cigarettes/day

• Expired breath carbon monoxide (CO) level \>8 ppm

• Have a smartphone capable of running software for ecological momentary assessment

• Open to exploring the possibility of quitting smoking

Locations
United States
North Carolina
North Pavilion
RECRUITING
Durham
Contact Information
Primary
Clinical Research Coordinator
ta141@duke.edu
919-907-9955
Backup
Clinical Research Coordinator
lgf12@duke.edu
984-327-6157
Time Frame
Start Date: 2025-04-15
Estimated Completion Date: 2027-07-30
Participants
Target number of participants: 60
Treatments
Experimental: Very Low Nicotine Cigarette (VLNC) Group
Participants in this condition will be provided with VLNCs and asked to switch to smoking only study cigarettes for 4 weeks.
Active_comparator: Normal Nicotine Cigarette (NNC) Group
Participants in this condition will be provided with NNCs and asked to switch to smoking only study cigarettes for 4 weeks.
Related Therapeutic Areas
Sponsors
Collaborators: National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Leads: Duke University

This content was sourced from clinicaltrials.gov